Growth factor regulation of proliferation and survival of multipotential stromal cells

Stem Cell Research and Therapy

Volumn 1, Issue 4, 2010, Pages

  Rodrigues, Melanie ^a   Griffith, Linda G ^b   Wells, Alan ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; WNT PROTEIN;

CARTILAGE CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL FATE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPLANTATION; CULTURE MEDIUM; ENGRAFTMENT; HEART INFARCTION; HUMAN; MULTIPOTENTIAL STROMAL CELL; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TRAUMATIC BRAIN INJURY;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL- AND TISSUE-BASED THERAPY; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PLATELET-DERIVED GROWTH FACTOR; REGENERATION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT PROTEINS;

ANIMALIA;

EID: 80052343852     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt32     Document Type: Review

References (89)

1. The risk of congestive heart failure: sobering lessons from the Framingham Heart Study. Lloyd-Jones DM, Curr Cardiol Rep 2001 3 184 190 10.1007/s11886-001-0021-1 11305971
2. Heart failure: recent advances in prevention and treatment. Fonarow GC, Rev Cardiovasc Med 2000 1 25 33 54 12457149
3. Multilineage potential of adult human mesenchymal stem cells. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR, Science 1999 284 143 147 10.1126/science.284.5411.143 10102814 (Pubitemid 29282067)
4. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. Caplan AI, J Cell Physiol 2007 213 341 347 10.1002/jcp.21200 17620285 (Pubitemid 47509711)
5. Cardiomyocytes can be generated from marrow stromal cells in vitro. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S, J Clin Invest 1999 103 697 705 10.1172/JCI5298 10074487 (Pubitemid 29122423)
6. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Kopen GC, Prockop DJ, Phinney DG, Proc Natl Acad Sci USA 1999 96 10711 10716 10.1073/pnas.96.19.10711 10485891 (Pubitemid 29442209)
7. Therapeutic potential of genetically modified mesenchymal stem cells. Kumar S, Chanda D, Ponnazhagan S, Gene Ther 2008 15 711 715 10.1038/gt.2008.35 18356815 (Pubitemid 351627354)
8. Bone marrow cells regenerate infarcted myocardium. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P, Nature 2001 410 701 705 10.1038/35070587 11287958 (Pubitemid 32290358)
9. Scaffold-free cell sheet injection results in bone formation. Akahane M, Shigematsu H, Tadokoro M, Ueha T, Matsumoto T, Tohma Y, Kido A, Imamura T, Tanaka Y, J Tissue Eng Regen Med 2010 4 404 411 10.1002/term.259 20084634
10. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, Rottoli D, Angioletti S, Benigni A, Perico N, Alison M, Remuzzi G, J Am Soc Nephrol 2004 15 1794 1804 10.1097/01.ASN.0000128974.07460.34 15213267 (Pubitemid 38822058)
11. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Hofstetter CP, Schwarz EJ, Hess D, Widenfalk J, El Manira A, Prockop DJ, Olson L, Proc Natl Acad Sci USA 2002 99 2199 2204 10.1073/pnas.042678299 11854516 (Pubitemid 34169038)
12. Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Osaka M, Honmou O, Murakami T, Nonaka T, Houkin K, Hamada H, Kocsis JD, Brain Res 2010 1343 226 235 10.1016/j.brainres.2010.05.011 20470759
13. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Tsutsumi S, Shimazu A, Miyazaki K, Pan H, Koike C, Yoshida E, Takagishi K, Kato Y, Biochem Biophys Res Commun 2001 288 413 419 10.1006/bbrc.2001.5777 11606058 (Pubitemid 33022499)
14. Mesenchymal stem cells and their potential as cardiac therapeutics. Pittenger MF, Martin BJ, Circ Res 2004 95 9 20 10.1161/01.RES.0000135902.99383. 6f 15242981 (Pubitemid 38931831)
15. Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. Tamama K, Kawasaki H, Wells A, J Biomed Biotechnol 2010 795385
16. A quantitative randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis M, Wilensky RL, Eur Heart J 2006 27 1114 1122 10.1093/eurheartj/ehi818 16510464
17. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE, J Mol Cell Cardiol 2001 33 907 921 10.1006/jmcc.2001.1367 11343414 (Pubitemid 32545326)
18. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxiaregulated heme oxygenase-1 vector. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI, J Am Coll Cardiol 2005 46 1339 1350 10.1016/j.jacc.2005.05. 079 16198853 (Pubitemid 41615559)
19. Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart. van der Bogt KE, Schrepfer S, Yu J, Sheikh AY, Hoyt G, Govaert JA, Velotta JB, Contag CH, Robbins RC, Wu JC, Transplantation 2009 87 642 652 10.1097/TP.0b013e31819609d9 19295307
20. Changes in host blood factors and brain glia accompanying the functional recovery after systemic administration of bone marrow stem cells in ischemic stroke rats. Yang M, Wei X, Li J, Heinel LA, Rosenwasser R, Iacovitti L, Cell Transplant 2010 20412636
21. Modification of mesenchymal stem cells for cardiac regeneration. Song H, Song BW, Cha MJ, Choi IG, Hwang KC, Expert Opin Biol Ther 2010 10 309 319 10.1517/14712590903455997 20132054
22. Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Fan VH, Tamama K, Au A, Littrell R, Richardson LB, Wright JW, Wells A, Griffith LG, Stem Cells 2007 25 1241 1251 10.1634/stemcells.2006-0320 17234993 (Pubitemid 46684884)
23. Cell viability in scoliotic discs in relation to disc deformity and nutrient levels. Bibby SR, Fairbank JC, Urban MR, Urban JP, Spine (Phila Pa 1976) 2002 27 2220 2228 discussion 2227-2228 12394897
24. Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. Arminan A, Gandia C, Garcia-Verdugo JM, Lledo E, Trigueros C, Ruiz-Sauri A, Minana MD, Solves P, Paya R, Montero JA, Sepulveda P, J Am Coll Cardiol 2010 55 2244 2253 10.1016/j.jacc.2009.08.092 20466205
25. Intra-myocardial delivery of mesenchymal stem cells ameliorates left ventricular and cardiomyocyte contractile dysfunction following myocardial infarction. Li Q, Turdi S, Thomas DP, Zhou T, Ren J, Toxicol Lett 2010 195 119 126 10.1016/j.toxlet.2010.03.009 20303399
26. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. Zhen G, Xue Z, Zhao J, Gu N, Tang Z, Xu Y, Zhang Z, Cytotherapy 2010 12 605 614 10.3109/14653241003745888 20429787
27. Why are MSCs therapeutic? New data: new insight. Caplan AI, J Pathol 2009 217 318 324 10.1002/path.2469 19023885
28. Mesenchymal stem cells as trophic mediators. Caplan AI, Dennis JE, J Cell Biochem 2006 98 1076 1084 10.1002/jcb.20886 16619257 (Pubitemid 44128350)
29. Effects of platelet-derived growth factor on bone formation in vitro. Canalis E, McCarthy TL, Centrella M, J Cell Physiol 1989 140 530 537 10.1002/jcp.1041400319 2777891 (Pubitemid 19241771)
30. Role of active and latent transforming growth factor beta in bone formation. Bonewald LF, Dallas SL, J Cell Biochem 1994 55 350 357 10.1002/jcb.240550312 7962167 (Pubitemid 24218811)
31. TGF- signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor- Smads. van der Kraan PM, Blaney Davidson EN, Blom A, van den Berg WB, Osteoarthritis Cartilage 2009 17 1539 1545 10.1016/j.joca.2009.06.008 19583961
32. Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF- signaling. Longobardi L, O'Rear L, Aakula S, Johnstone B, Shimer K, Chytil A, Horton WA, Moses HL, Spagnoli A, J Bone Miner Res 2006 21 626 636 10.1359/jbmr.051213 16598383
33. In vitro proliferation and chondrogenic differentiation of rat bone marrow stem cells cultured with gelatin hydrogel microspheres for TGF-1 release. Ogawa T, Akazawa T, Tabata Y, J Biomater Sci Polym Ed 2010 21 609 621 10.1163/156856209X434638 20338095
34. Impact of growth factors and PTHrP on early and late chondrogenic differentiation of human mesenchymal stem cells. Weiss S, Hennig T, Bock R, Steck E, Richter W, J Cell Physiol 2010 223 84 93 20049852
35. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. Luu HH, Song WX, Luo X, Manning D, Luo J, Deng ZL, Sharff KA, Montag AG, Haydon RC, He TC, J Orthop Res 2007 25 665 677 10.1002/jor.20359 17290432 (Pubitemid 46730519)
36. Gene therapy: adenovirus-mediated human bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo. Lou J, Xu F, Merkel K, Manske P, J Orthop Res 1999 17 43 50 10.1002/jor.1100170108 10073646 (Pubitemid 29096004)
37. Repair of large cranial defects by hBMP-2 expressing bone marrow stromal cells: comparison between alginate and collagen type I systems. Chang SC, Chung HY, Tai CL, Chen PK, Lin TM, Jeng LB, J Biomed Mater Res A 2010 94 433 441 20186742
38. BMP-3 promotes mesenchymal stem cell proliferation through the TGF-/activin signaling pathway. Stewart A, Guan H, Yang K, J Cell Physiol 2010 223 658 666 20143330
39. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Simmons CA, Alsberg E, Hsiong S, Kim WJ, Mooney DJ, Bone 2004 35 562 569 10.1016/j.bone.2004.02.027 15268909 (Pubitemid 38953205)
40. Functions of transforming growth factor-beta family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes. Valcourt U, Gouttenoire J, Moustakas A, Herbage D, Mallein-Gerin F, J Biol Chem 2002 277 33545 33558 10.1074/jbc.M202086200 12082094
41. Non-Smad pathways in TGF- signaling. Zhang YE, Cell Res 2009 19 128 139 10.1038/cr.2008.328 19114990
42. Involvement of ERK in BMP-2 induced osteoblastic differentiation of mesenchymal progenitor cell line C3H10T1/2. Lou J, Tu Y, Li S, Manske PR, Biochem Biophys Res Commun 2000 268 757 762 10.1006/bbrc.2000.2210 10679278 (Pubitemid 30150864)
43. Effect of fibroblast growth factor-2 on equine mesenchymal stem cell monolayer expansion and chondrogenesis. Stewart AA, Byron CR, Pondenis H, Stewart MC, Am J Vet Res 2007 68 941 945 10.2460/ajvr.68.9.941 17764407 (Pubitemid 47408323)
44. FGF-4 increases in vitro expansion rate of human adult bone marrow-derived mesenchymal stem cells. Farre J, Roura S, Prat-Vidal C, Soler-Botija C, Llach A, Molina CE, Hove-Madsen L, Cairo JJ, Godia F, Bragos R, Cinca J, Bayes-Genis A, Growth Factors 2007 25 71 76 10.1080/08977190701345200 17852409 (Pubitemid 47487573)
45. Possibility of selection of chondrogenic progenitor cells by telomere length in FGF-2-expanded mesenchymal stromal cells. Yanada S, Ochi M, Kojima K, Sharman P, Yasunaga Y, Hiyama E, Cell Prolif 2006 39 575 584 10.1111/j.1365-2184.2006.00397.x 17109640 (Pubitemid 44760207)
46. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Bianchi G, Banfi A, Mastrogiacomo M, Notaro R, Luzzatto L, Cancedda R, Quarto R, Exp Cell Res 2003 287 98 105 10.1016/S0014-4827(03)00138-1 12799186 (Pubitemid 36683205)
47. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M, Dulong J, Monnier D, Gourmelon P, Gorin NC, Sensebe L, Blood 2010 115 1549 1553 10.1182/blood-2009-05-219907 20032501
48. Aging-related attenuation of EGF receptor signaling is mediated in part by increased protein tyrosine phosphatase activity. Tran KT, Rusu SD, Satish L, Wells A, Exp Cell Res 2003 289 359 367 10.1016/S0014-4827(03)00287-8 14499637 (Pubitemid 37117422)
49. Aging fibroblasts present reduced epidermal growth factor (EGF) responsiveness due to preferential loss of EGF receptors. Shiraha H, Gupta K, Drabik K, Wells A, J Biol Chem 2000 275 19343 19351 10.1074/jbc.M000008200 10764734 (Pubitemid 30422908)
50. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Battula VL, Bareiss PM, Treml S, Conrad S, Albert I, Hojak S, Abele H, Schewe B, Just L, Skutella T, Buhring HJ, Differentiation 2007 75 279 291 10.1111/j.1432-0436.2006.00139.x 17288545 (Pubitemid 46434949)
51. PDGF, TGF-, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS, Tanavde V, Blood 2008 112 295 307 10.1182/blood-2007-07-103697 18332228
52. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Pons J, Huang Y, Arakawa-Hoyt J, Washko D, Takagawa J, Ye J, Grossman W, Su H, Biochem Biophys Res Commun 2008 376 419 422 10.1016/j.bbrc.2008.09.003 18789891
53. Bioenergetic and functional consequences of stem cell-based VEGF delivery in pressure-overloaded swine hearts. Wang X, Hu Q, Mansoor A, Lee J, Wang Z, Lee T, From AH, Zhang J, Am J Physiol Heart Circ Physiol 2006 290 1393 H1405 10.1152/ajpheart.00871.2005 16387794
54. A promising strategy for the treatment of ischemic heart disease: mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Gao F, He T, Wang H, Yu S, Yi D, Liu W, Cai Z, Can J Cardiol 2007 23 891 898 17876381 (Pubitemid 350011270)
55. Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. Ball SG, Shuttleworth CA, Kielty CM, J Cell Mol Med 2007 11 1012 1030 10.1111/j.1582-4934.2007.00120.x 17979880 (Pubitemid 350037047)
56. Role of c-Jun N-terminal kinase in the PDGF-induced proliferation and migration of human adipose tissue-derived mesenchymal stem cells. Kang YJ, Jeon ES, Song HY, Woo JS, Jung JS, Kim YK, Kim JH, J Cell Biochem 2005 95 1135 1145 10.1002/jcb.20499 15962287 (Pubitemid 41420121)
57. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. Tokunaga A, Oya T, Ishii Y, Motomura H, Nakamura C, Ishizawa S, Fujimori T, Nabeshima Y, Umezawa A, Kanamori M, Kimura T, Sasahara M, J Bone Miner Res 2008 23 1519 1528 10.1359/jbmr.080409 18410236
58. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M, Science 2005 308 1472 1477 10.1126/science.1107627 15933201 (Pubitemid 40791302)
59. Inhibition of platelet-derived growth factor receptor beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S, Bornhauser M, Cell Prolif 2007 40 355 366 10.1111/j.1365-2184.2007.00438.x 17531080 (Pubitemid 46802187)
60. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Tamama K, Fan VH, Griffith LG, Blair HC, Wells A, Stem Cells 2006 24 686 695 10.1634/stemcells.2005-0176 16150920 (Pubitemid 44464773)
61. Platelet derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, Jelinek DF, Kay NE, Blood 2010
62. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Neuss S, Becher E, Woltje M, Tietze L, Jahnen-Dechent W, Stem Cells 2004 22 405 414 10.1634/stemcells.22-3-405 15153617 (Pubitemid 38736624)
63. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Furge KA, Zhang YW, Vande Woude GF, Oncogene 2000 19 5582 5589 10.1038/sj.onc.1203859 11114738
64. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Forte G, Minieri M, Cossa P, Antenucci D, Sala M, Gnocchi V, Fiaccavento R, Carotenuto F, De Vito P, Baldini PM, Prat M, Di Nardo P, Stem Cells 2006 24 23 33 10.1634/stemcells.2004-0176 16100005
65. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Krampera M, Pasini A, Rigo A, Scupoli MT, Tecchio C, Malpeli G, Scarpa A, Dazzi F, Pizzolo G, Vinante F, Blood 2005 106 59 66 10.1182/blood-2004-09-3645 15755902 (Pubitemid 40967175)
66. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. Boland GM, Perkins G, Hall DJ, Tuan RS, J Cell Biochem 2004 93 1210 1230 10.1002/jcb.20284 15486964 (Pubitemid 44264134)
67. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. Baksh D, Boland GM, Tuan RS, J Cell Biochem 2007 101 1109 1124 10.1002/jcb.21097 17546602 (Pubitemid 47253714)
68. Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. Baksh D, Tuan RS, J Cell Physiol 2007 212 817 826 10.1002/jcp.21080 17458904 (Pubitemid 47267551)
69. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. Chang J, Sonoyama W, Wang Z, Jin Q, Zhang C, Krebsbach PH, Giannobile W, Shi S, Wang CY, J Biol Chem 2007 282 30938 30948 10.1074/jbc.M702391200 17720811 (Pubitemid 350035235)
70. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM, Kassem M, J Bone Miner Res 2007 22 1720 1731 10.1359/jbmr.070721 17680723 (Pubitemid 351235138)
71. Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. de Boer J, Siddappa R, Gaspar C, van Apeldoorn A, Fodde R, van Blitterswijk C, Bone 2004 34 818 826 10.1016/j.bone.2004.01.016 15121013 (Pubitemid 38581127)
72. Combination of chemokine and angiogenic factor genes and mesenchymal stem cells could enhance angiogenesis and improve cardiac function after acute myocardial infarction in rats. Tang J, Wang J, Zheng F, Kong X, Guo L, Yang J, Zhang L, Huang Y, Mol Cell Biochem 2010 339 107 118 10.1007/s11010-009-0374-0 20058054
73. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME, Cell 1999 96 857 868 10.1016/S0092-8674(00)80595-4 10102273 (Pubitemid 29165088)
74. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR, Shock 2010 33 24 30 10.1097/SHK.0b013e3181b7d137 19996917
75. Intracerebral transplantation of marrow stromal cells cultured with neurotrophic factors promotes functional recovery in adult rats subjected to traumatic brain injury. Mahmood A, Lu D, Wang L, Chopp M, J Neurotrauma 2002 19 1609 1617 10.1089/089771502762300265 12542861 (Pubitemid 36026216)
76. Influence of cell treatment with PDGF-BB and reperfusion on cardiac persistence of mononuclear and mesenchymal bone marrow cells after transplantation into acute myocardial infarction in rats. Krausgrill B, Vantler M, Burst V, Raths M, Halbach M, Frank K, Schynkowski S, Schenk K, Hescheler J, Rosenkranz S, Muller-Ehmsen J, Cell Transplant 2009 18 847 853 10.3727/096368909X471134 19520046
77. Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity. Iyer AK, Tran KT, Borysenko CW, Cascio M, Camacho CJ, Blair HC, Bahar I, Wells A, J Cell Physiol 2007 211 748 758 10.1002/jcp.20986 17311283 (Pubitemid 46683043)
78. Sustained epidermal growth factor receptor levels and activation by tethered ligand binding enhances osteogenic differentiation of multi-potent marrow stromal cells. Platt MO, Roman AJ, Wells A, Lauffenburger DA, Griffith LG, J Cell Physiol 2009 221 306 317 10.1002/jcp.21854 19544388
79. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Muller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz MP, Horwitz EM, Conte P, Handgretinger R, Dominici M, Cytotherapy 2006 8 437 444 10.1080/14653240600920782 17050248 (Pubitemid 44596996)
80. Human marrow mesenchymal stem cell culture: serum-free medium allows better expansion than classical alpha-MEM medium. Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M, Bron D, Lagneaux L, Eur J Haematol 2006 76 309 316 10.1111/j.1600-0609.2005.00611.x 16519702 (Pubitemid 43362939)
81. A novel serumfree medium for the expansion of human mesenchymal stem cells. Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC, Stem Cell Res Ther 2010 1 8 10.1186/scrt8 20504289
82. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, Bae JW, Oh BH, Park YB, Kim HS, J Am Coll Cardiol 2008 51 933 943 10.1016/j.jacc.2007.11.040 18308163 (Pubitemid 351282455)
83. Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Zhang ZX, Guan LX, Zhang K, Wang S, Cao PC, Wang YH, Wang Z, Dai LJ, Cell Biol Int 2007 31 645 648 10.1016/j.cellbi.2006.11.025 17207646 (Pubitemid 46660640)
84. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Dahl JA, Duggal S, Coulston N, Millar D, Melki J, Shahdadfar A, Brinchmann JE, Collas P, Int J Dev Biol 2008 52 1033 1042 10.1387/ijdb.082663jd 18956336
85. Polymeric system for dual growth factor delivery. Richardson TP, Peters MC, Ennett AB, Mooney DJ, Nat Biotechnol 2001 19 1029 1034 10.1038/nbt1101-1029 11689847 (Pubitemid 33041886)
86. Engineering principles of clinical cell-based tissue engineering. Muschler GF, Nakamoto C, Griffith LG, J Bone Joint Surg Am 2004 86-A 1541 1558 15252108 (Pubitemid 38886548)
87. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. Ball SG, Shuttleworth CA, Kielty CM, J Cell Biol 2007 177 489 500 10.1083/jcb.200608093 17470632 (Pubitemid 46718277)
88. Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. Agata H, Watanabe N, Ishii Y, Kubo N, Ohshima S, Yamazaki M, Tojo A, Kagami H, Biochem Biophys Res Commun 2009 382 353 358 10.1016/j.bbrc.2009.03.023 19281797
89. Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow-derived mesenchymal stem cells. Pal R, Hanwate M, Jan M, Totey S, J Tissue Eng Regen Med 2009 3 163 174 10.1002/term.143 19229888